The estimated Net Worth of Dirk G. Brockstedt is at least $2.38 Million dollars as of 5 January 2024. Dirk Brockstedt owns over 898 units of RAPT Therapeutics stock worth over $53,693 and over the last 9 years he sold RAPT stock worth over $1,528,348. In addition, he makes $797,134 as Chief Scientific Officer at RAPT Therapeutics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Dirk Brockstedt RAPT stock SEC Form 4 insiders trading
Dirk has made over 49 trades of the RAPT Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 898 units of RAPT stock worth $20,456 on 5 January 2024.
The largest trade he's ever made was selling 65,223 units of RAPT Therapeutics stock on 15 December 2017 worth over $528,959. On average, Dirk trades about 6,936 units every 48 days since 2015. As of 5 January 2024 he still owns at least 27,820 units of RAPT Therapeutics stock.
You can see the complete history of Dirk Brockstedt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dirk Brockstedt biography
Dr. Dirk Brockstedt Ph.D. serves as Chief Scientific Officer of the Company.D. was Senior Vice President of the Company. Since October 2017, he has also served as Executive in Residence at ShangPharma Innovation Inc., a healthcare investment company. From September 2011 to December 2017, he served as Senior Vice President of Research and Development and most recently as Executive Vice President of Research and Development at Aduro Biotech, Inc., a biopharmaceutical company. Dr. Brockstedt served as Director of Research at Anza Therapeutics, Inc. from 2007 to 2009, Director of Immunology at Cerus Corporation from 2002 to 2007 and Senior Research Scientist at Aventis Pharmaceuticals, Inc. from 1999 to 2002, each a biopharmaceutical company. Prior to that he was a post-doctoral fellow at the Stanford School of Medicine in the Department of Pathology. Dr. Brockstedt received a Ph.D. in Microbiology from the University of Kiel (graduate work performed at Stanford University) and an M.S. in Microbiology from the University of Kiel.
What is the salary of Dirk Brockstedt?
As the Chief Scientific Officer of RAPT Therapeutics, the total compensation of Dirk Brockstedt at RAPT Therapeutics is $797,134. There are 2 executives at RAPT Therapeutics getting paid more, with Rodney Young having the highest compensation of $2,296,220.
How old is Dirk Brockstedt?
Dirk Brockstedt is 51, he's been the Chief Scientific Officer of RAPT Therapeutics since 2019. There are 12 older and 2 younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics, Inc. is Mary Gray, 67, who is the Independent Director.
What's Dirk Brockstedt's mailing address?
Dirk's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at RAPT Therapeutics
Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.
What does RAPT Therapeutics do?
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
What does RAPT Therapeutics's logo look like?
Complete history of Dirk Brockstedt stock trades at Aduro BioTech and RAPT Therapeutics
RAPT Therapeutics executives and stock owners
RAPT Therapeutics executives and other stock owners filed with the SEC include:
-
Rodney Young,
Chief Financial Officer -
Brian Wong,
President, Chief Executive Officer, Director -
Dirk Brockstedt,
Chief Scientific Officer -
Dr. Brian Russell Wong M.D., Ph.D.,
CEO, Pres & Director -
Dr. William Ho,
Chief Medical Officer -
Dr. Dirk G. Brockstedt Ph.D.,
Chief Scientific Officer -
Mary Gray,
Independent Director -
Wendye Robbins,
Independent Director -
William Rieflin,
Independent Director -
Linda Kozick,
Independent Director -
Michael Giordano,
Independent Director -
Peter Svennilson,
Director -
William Ho,
Chief Medical Officer -
Lisa Moore,
Vice President - Business Development and Strategy -
Phyllis Gray,
Vice President of Human Resources -
Paul Kassner,
Senior Vice President - Quantitative and Computational Biology -
Dr. David Wustrow,
Sr. VP of Drug Discovery & Preclinical Devel. -
Dr. Paul Kassner,
Sr. VP of Quantitative & Computational Biology -
Steve Young Ph.D.,
VP of Technology -
Rodney K. B. Young,
CFO, Principal Accounting Officer & Sec. -
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Perkins Caufield & Byers Xv...,
-
David V Goeddel,
Director -
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Group Ii, Lp Column Group I...,
-
Fund L.P.Topspin Biotech Fu...,
-
Karen C Lam,
VP, Finance and Controller -
Lori Lyons Williams,